MA67365B1 - Dérivés de benzisoxazole sulfonamide - Google Patents

Dérivés de benzisoxazole sulfonamide

Info

Publication number
MA67365B1
MA67365B1 MA67365A MA67365A MA67365B1 MA 67365 B1 MA67365 B1 MA 67365B1 MA 67365 A MA67365 A MA 67365A MA 67365 A MA67365 A MA 67365A MA 67365 B1 MA67365 B1 MA 67365B1
Authority
MA
Morocco
Prior art keywords
sup
compounds
derivatives
benzisoxazole
sulfonaminate
Prior art date
Application number
MA67365A
Other languages
English (en)
Inventor
Robert Arnold Kumpf
Pei-Pei Kung
Scott Channing Sutton
Samantha Elizabeth GREASLEY
Robert Louis Hoffman
Paul Francis Richardson
Ylva Elisabet Bergman BOZIKIS
Oleg Brodsky
Michelle Ang CAMERINO
Paul Anthony Stupple
Original Assignee
Pfizer Inc.
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Ctxt Pty Ltd filed Critical Pfizer Inc.
Publication of MA67365B1 publication Critical patent/MA67365B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des composés de formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci, dans lesquels le cycle A, R<sup>1</sup>-R<sup>8</sup> et n sont définis ici. Les nouveaux dérivés de sulfonamide de benzisoxazole sont utiles dans le traitement de la croissance cellulaire anormale, telle que le cancer, chez les patients. Des modes de réalisation supplémentaires concernent des compositions pharmaceutiques contenant les composés et des procédés d'utilisation des composés et des compositions dans le traitement de la croissance cellulaire anormale chez les patients.
MA67365A 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide MA67365B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863199P 2019-06-18 2019-06-18
US201962953223P 2019-12-24 2019-12-24
US202063025278P 2020-05-15 2020-05-15
EP23203023.9A EP4299135B1 (fr) 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide

Publications (1)

Publication Number Publication Date
MA67365B1 true MA67365B1 (fr) 2025-10-31

Family

ID=71738189

Family Applications (1)

Application Number Title Priority Date Filing Date
MA67365A MA67365B1 (fr) 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide

Country Status (34)

Country Link
US (3) US11492346B2 (fr)
EP (2) EP4299135B1 (fr)
JP (2) JP7352662B2 (fr)
KR (1) KR102823056B1 (fr)
CN (1) CN114364672B (fr)
AU (3) AU2020296361A1 (fr)
BR (1) BR112021025528A2 (fr)
CA (1) CA3143666C (fr)
CL (1) CL2021003372A1 (fr)
CO (1) CO2021017504A2 (fr)
CR (1) CR20210627A (fr)
DK (2) DK4299135T3 (fr)
EC (1) ECSP21091615A (fr)
ES (2) ES2969616T3 (fr)
FI (2) FI3986890T3 (fr)
HR (2) HRP20231501T1 (fr)
HU (1) HUE064683T2 (fr)
IL (1) IL288802B2 (fr)
LT (2) LT3986890T (fr)
MA (1) MA67365B1 (fr)
MD (2) MD3986890T3 (fr)
MX (1) MX2021016085A (fr)
MY (1) MY210207A (fr)
PE (1) PE20220808A1 (fr)
PH (1) PH12021553107A1 (fr)
PL (2) PL4299135T3 (fr)
PT (2) PT3986890T (fr)
PY (1) PY2027460A (fr)
RS (2) RS67276B1 (fr)
SI (2) SI4299135T1 (fr)
TW (1) TWI787620B (fr)
UA (1) UA129891C2 (fr)
UY (1) UY38752A (fr)
WO (1) WO2020254946A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
SI4299135T1 (sl) 2019-06-18 2025-12-31 Pfizer Inc. Benzizoksazolni sulfonamidni derivati
WO2020254989A1 (fr) * 2019-06-19 2020-12-24 Pfizer Inc. Dérivés de cycloalkyl et hétérocycloalkyl benzisoxazole sulfonamide
US20220024919A1 (en) * 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
PT4181920T (pt) * 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
WO2022187688A1 (fr) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Composés de liaison de kras covalents à des fins thérapeutiques
WO2022187693A1 (fr) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Composés de liaison à cdk2 covalents utilisés à des fins thérapeutiques
JP2024521141A (ja) * 2021-05-21 2024-05-28 アウリジーン オンコロジー リミテッド Kat6a阻害剤としての縮合イソオキサゾリル化合物
US20240400545A1 (en) 2021-07-05 2024-12-05 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
EP4385989A4 (fr) * 2021-08-10 2024-12-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Dérivé de sulfonamide, son procédé de préparation et son utilisation médicale
MX2024005839A (es) 2021-11-16 2024-06-26 Insilico Medicine Ip Ltd Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos.
WO2023114710A1 (fr) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Composés benzoisoxazolyle fusionnés en tant qu'inhibiteurs de kat6a
CN116621859B (zh) * 2022-02-18 2026-06-12 山东轩竹医药科技有限公司 三并环类kat6抑制剂
US12187732B2 (en) * 2022-03-28 2025-01-07 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
AU2023295547A1 (en) * 2022-06-16 2025-01-09 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
JP2025533719A (ja) 2022-07-29 2025-10-09 ファイザー・インク がんの治療のためのkat6阻害剤を含む投与レジメン
CN120476113A (zh) * 2022-12-20 2025-08-12 杭州中美华东制药有限公司 具有sting抑制作用的含肟化合物及其药物组合物和用途
CN120569381A (zh) * 2023-02-10 2025-08-29 江苏恒瑞医药股份有限公司 一种磺酰胺衍生物结晶形式及其制备方法
EP4680226A2 (fr) 2023-03-16 2026-01-21 Olema Pharmaceuticals, Inc. Inhibiteurs de kat6a de type acylsulfonamides
EP4692094A1 (fr) * 2023-03-27 2026-02-11 Beijing Konruns Pharmaceutical Co., Ltd. Composé sulfonamide, composition pharmaceutique de celui-ci et utilisation associée
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
AR132470A1 (es) * 2023-04-19 2025-07-02 Insilico Medicine Ip Ltd Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo
KR20260016479A (ko) * 2023-04-25 2026-02-03 인실리코 메디신 아이피 리미티드 결정질 리신 아세틸트랜스퍼라제 6a (kat6a) 억제제 및 그의 용도
AU2024290895A1 (en) * 2023-07-04 2026-01-29 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Kat6 inhibitor
AU2024325442A1 (en) 2023-08-14 2026-03-26 Shanghai Henlius Biologics Co., Ltd. Sulfonamide compound, and preparation method therefor and use thereof
CN122003411A (zh) * 2023-09-27 2026-05-08 爱索斯特里克斯公司 Myst抑制剂
WO2025098417A1 (fr) * 2023-11-08 2025-05-15 再和医药科技(苏州)有限公司 Composé sulfonamide et son utilisation
WO2025141469A1 (fr) 2023-12-26 2025-07-03 Pfizer Inc. Forme cristalline de 2-méthoxy-n-4-méthoxy-6-[(1h-pyrazol-1-yl)méthyl]-1,2-benzoxazol-3-yl}benzène-1-sulfonamide
WO2026003716A1 (fr) 2024-06-27 2026-01-02 Pfizer Inc. Procédé de préparation de n-(6-((1h-pyrazol-1-yl) méthyl)-4-méthoxybenzo[d]isoxazol-3-yl)-2-méthoxybenzènesulfonamide
WO2026053122A1 (fr) 2024-09-04 2026-03-12 Dana-Farber Cancer Institute, Inc. Procédés de traitement de cancers sensibles aux rétinoïdes
WO2026057050A1 (fr) * 2024-09-14 2026-03-19 北京康辰药业股份有限公司 Formes cristallines d'un composé sulfonamide ou d'un sel pharmaceutiquement acceptable de celui-ci
WO2026128808A1 (fr) 2024-12-13 2026-06-18 Ideaya Biosciences, Inc. Inhibiteurs de kat6 et/ou de kat7 destinés aux méthodes de traitement du cancer
WO2026133163A1 (fr) 2024-12-19 2026-06-25 Pfizer Inc. Formes posologiques solides pelliculées pour le traitement de la dysgueusie
WO2026145581A1 (fr) * 2025-01-02 2026-07-09 齐鲁制药有限公司 Forme cristalline d'un inhibiteur kat6a/b, son procédé de préparation et son utilisation
WO2026144956A1 (fr) * 2025-01-02 2026-07-09 齐鲁制药有限公司 Polymorphe d'inhibiteur de kat6a/b

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2358031A (en) 1944-09-12 Substituted thiadiazoles
US3064003A (en) 1962-11-13 Carboxylic acid derivatives of sub-
US2525321A (en) 1949-01-07 1950-10-10 American Cyanamid Co Hydroxybenzenesulfonamidoisoxazoles and preparation of same
GB689281A (en) 1950-02-18 1953-03-25 Lunbeck Corp Improvements in or relating to the production of sulphanilamido-thiadiazoles
DE1102745B (de) 1959-06-06 1961-03-23 Boehringer & Soehne Gmbh Verfahren zur Herstellung von 5-Sulfanilamidoisoxazolen
BE617370A (fr) 1961-05-09 1962-11-08 Ciba Geigy Procédé de préparation du 2,5-di-[benzoxazolyl-(2')]-thiofène
US3332942A (en) 1962-11-02 1967-07-25 White Lab Inc Substituted thiadiazoles
JPS498255B1 (fr) 1970-10-08 1974-02-25
US3960854A (en) 1972-03-20 1976-06-01 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
US3951967A (en) 1972-03-20 1976-04-20 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
DE2617809C2 (de) 1976-04-23 1984-09-20 Basf Ag, 6700 Ludwigshafen Verfahren zur Stabilisierung von Chromdioxid-Magnetpigmenten und seine Verwendung
JPS6042794B2 (ja) 1977-09-27 1985-09-25 三共株式会社 イソオキサゾリウム塩,およびその製造方法
US4251664A (en) 1978-05-24 1981-02-17 Henkel Corporation Sulfonamidothiadiazoles, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS603685B2 (ja) 1980-04-15 1985-01-30 日本コロムビア株式会社 絵入りレコ−ド盤の製造方法
GB8427618D0 (en) 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS63238006A (ja) 1987-03-26 1988-10-04 Shionogi & Co Ltd イモチ防除剤
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ231534A (en) 1988-11-29 1992-02-25 Warner Lambert Co 3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions
JPH03258771A (ja) 1990-03-09 1991-11-19 Tosoh Corp スルホンアミド誘導体、その製法及びそれを有効成分として含有する除草剤
JP2902834B2 (ja) 1991-10-09 1999-06-07 本田技研工業株式会社 自己伸縮型マウント
TW224462B (fr) 1992-02-24 1994-06-01 Squibb & Sons Inc
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
FI941826L (fi) 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
JP3901229B2 (ja) 1994-05-13 2007-04-04 Ntn株式会社 耐熱・潤滑性樹脂組成物
EP0819125B1 (fr) 1995-04-04 2003-06-18 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- et biphenyl sulfonamides et leurs derives modulant l'activite de l'endotheline
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AU7179598A (en) 1996-11-13 1998-06-03 Cephalon, Inc. Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
TR200202738T2 (tr) 1997-04-28 2003-03-21 Texas Biotechnology Corporation Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU2456701A (en) 1999-12-31 2001-07-16 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
WO2001064642A2 (fr) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides et inhibiteurs connexes du facteur xa
GB0127344D0 (en) 2001-11-14 2002-01-02 Cancer Res Ventures Ltd Assay method
EP1461327A1 (fr) 2001-11-22 2004-09-29 Biovitrum Ab Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1
JP2003292485A (ja) 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
AU2004240885A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I
WO2004113310A1 (fr) 2003-06-25 2004-12-29 Biovitrum Ab Utilisation d'un inhibiteur de compose de type 1 11-b-hydroxysteroide deshydrogenase type 1 destine a faciliter la cicatrisation d'une plaie
CA2533626A1 (fr) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Derives de quinolinone en tant qu'inhibiteurs de c-fms kinase
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
KR20060073930A (ko) 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (fr) 2003-11-13 2005-06-02 Abbott Laboratories Promoteurs de l'apoptose contenant n-acylsulfonamide
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
NZ554493A (en) 2004-10-12 2009-09-25 Decode Genetics Ehf Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
BRPI0610258A2 (pt) 2005-04-26 2012-09-25 Hypnion Inc composto ou um sal farmaceuticamente eficaz do mesmo, composição farmacêutica, e, uso de um composto
ATE461925T1 (de) 2005-04-26 2010-04-15 Hypnion Inc Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung
EP1888558B1 (fr) 2005-05-16 2011-10-05 Vertex Pharmaceuticals, Inc. Derives bicycliques en tant que modulateurs de canaux ioniques
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
EP1937657A1 (fr) 2005-10-06 2008-07-02 Sanofi-Aventis N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides : procedes de preparation et utilisation comme produits pharmaceutiques
RU2008113209A (ru) 2005-10-06 2009-10-10 Санофи-Авентис (Fr) Бициклические {1, 3, 4}тиадиазол-2-иламиды арилсульфоновой кислоты, способы их получения и их использование в качестве фармацевтических средств
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
WO2007075895A2 (fr) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Derives heterocycliques utilises comme modulateurs de canaux ioniques
WO2008022286A2 (fr) 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US7749996B2 (en) 2006-11-20 2010-07-06 Alantos Pharmaceutical Holdings, Inc. Heterotricyclic metalloprotease inhibitors
WO2008089307A2 (fr) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン, インコーポレイテッド ナトリウムチャネル阻害物質
EP2215066A1 (fr) 2007-11-01 2010-08-11 Sirtris Pharmaceuticals, Inc. Dérivés d'amide comme modulateurs de sirtuines
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
KR20100101165A (ko) 2007-12-26 2010-09-16 사노피-아벤티스 사이클릭 피리딜­n­(1,3,4)­티아디아졸­2­일-벤젠 설폰아미드, 이들의 제조방법 및 약제로서의 이들의 용도
CA2734254C (fr) 2008-08-13 2018-06-05 Smed-Ta/Td, Llc Implants d'apport de medicament
WO2010046780A2 (fr) 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
CN102438988B (zh) 2009-04-21 2015-06-24 内尔维阿诺医学科学有限公司 作为hsp90抑制剂的间苯二酚衍生物
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
HRP20151258T1 (hr) 2009-08-07 2016-02-26 Chugai Seiyaku Kabushiki Kaisha Derivat aminopirazola
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
WO2011085575A1 (fr) 2010-01-15 2011-07-21 江苏省农药研究所股份有限公司 Composés de formanilide hétérocyclique, leurs procédés de synthèse et leur utilisation
CN101747325A (zh) 2010-01-15 2010-06-23 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
CN101845043A (zh) 2010-01-15 2010-09-29 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
EP2593428B1 (fr) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant
EP2651405A2 (fr) 2010-12-14 2013-10-23 Electrophoretics Limited Inhibiteurs de caséine kinase 1 (ck1 )
EP2655334B1 (fr) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utilisables en vue du traitement de maladies
WO2012129562A2 (fr) 2011-03-24 2012-09-27 The Scripps Research Institute Composés et procédés pour l'induction de la chondrogenèse
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
CA2898680A1 (fr) 2013-03-15 2014-09-18 Genentech,Inc. Benzoxazoles substitues et leurs procedes d'utilisation
WO2015102929A1 (fr) 2013-12-30 2015-07-09 Novartis Ag Dérivés de sulfonamide tricycliques
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
TWI693227B (zh) 2014-04-23 2020-05-11 日商田邊三菱製藥股份有限公司 新穎二環性或三環性雜環化合物
JP5900759B2 (ja) 2014-09-25 2016-04-06 Toto株式会社 小便器
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017002120A1 (fr) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Inhibiteurs sélectifs de cellules sénescentes et leurs utilisations
WO2017098421A1 (fr) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Composés benzothiadiazine
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
EP3529245A4 (fr) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. Composés et utilisations de ces derniers
JP2020502064A (ja) * 2016-11-29 2020-01-23 エピザイム,インコーポレイティド スルホン酸基を含むkat阻害剤としての化合物
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
SI4299135T1 (sl) 2019-06-18 2025-12-31 Pfizer Inc. Benzizoksazolni sulfonamidni derivati

Also Published As

Publication number Publication date
CN114364672B (zh) 2024-09-06
IL288802B2 (en) 2025-08-01
EP3986890B9 (fr) 2025-04-16
LT3986890T (lt) 2023-12-11
MY210207A (en) 2025-09-03
CO2021017504A2 (es) 2022-01-17
CR20210627A (es) 2022-02-08
SI3986890T1 (sl) 2024-03-29
US11492346B2 (en) 2022-11-08
CN114364672A (zh) 2022-04-15
PH12021553107A1 (en) 2022-08-01
KR20220024671A (ko) 2022-03-03
TW202115048A (zh) 2021-04-16
FI3986890T3 (fi) 2024-01-15
CA3143666A1 (fr) 2020-12-24
KR102823056B1 (ko) 2025-06-23
ES2969616T3 (es) 2024-05-21
SI4299135T1 (sl) 2025-12-31
US12371425B2 (en) 2025-07-29
EP4299135B1 (fr) 2025-08-06
EP3986890B1 (fr) 2023-11-15
PT3986890T (pt) 2024-01-17
FI4299135T3 (fi) 2025-10-01
JP7352662B2 (ja) 2023-09-28
EP3986890A1 (fr) 2022-04-27
JP2022537285A (ja) 2022-08-25
HRP20251225T1 (hr) 2025-12-05
US20230174522A1 (en) 2023-06-08
UA129891C2 (uk) 2025-09-03
RS64931B9 (sr) 2025-06-30
AU2020296361A1 (en) 2022-01-06
BR112021025528A2 (pt) 2022-04-19
EP4299135A3 (fr) 2024-02-28
PL4299135T3 (pl) 2025-11-12
PE20220808A1 (es) 2022-05-20
HRP20231501T1 (hr) 2024-03-01
PL3986890T3 (pl) 2024-03-11
PY2027460A (es) 2021-11-16
ES3043899T3 (en) 2025-11-26
US20200399258A1 (en) 2020-12-24
CL2021003372A1 (es) 2022-10-07
MD3986890T2 (ro) 2024-04-30
MD3986890T3 (ro) 2025-07-31
PT4299135T (pt) 2025-10-09
DK4299135T3 (da) 2025-09-08
IL288802B1 (en) 2025-04-01
CA3143666C (fr) 2024-06-11
MD4299135T2 (ro) 2025-11-30
MX2021016085A (es) 2022-04-20
LT4299135T (lt) 2025-09-10
AU2023274178A1 (en) 2024-02-15
IL288802A (en) 2022-02-01
US20260062406A1 (en) 2026-03-05
WO2020254946A1 (fr) 2020-12-24
RS64931B1 (sr) 2023-12-29
RS67276B1 (sr) 2025-10-31
TWI787620B (zh) 2022-12-21
EP4299135A2 (fr) 2024-01-03
ECSP21091615A (es) 2022-01-31
UY38752A (es) 2021-01-29
DK3986890T3 (da) 2023-12-18
JP2023175821A (ja) 2023-12-12
AU2026200976A1 (en) 2026-03-05
HUE064683T2 (hu) 2024-04-28

Similar Documents

Publication Publication Date Title
TN2009000544A1 (fr) Derives de benzimidazole
EP4299135A3 (fr) Dérivés de benzisoxazole sulfonamide
MA30403B1 (fr) Derives d&#39;acides cycloalkylamines et leurs compositions pharmaceutiques
MA54327B1 (fr) Inhibiteurs de kras g12c
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA58498B1 (fr) Agonistes hétérocycliques de glp-1
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA55890B1 (fr) Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu&#39;inhibiteurs de kinases dépendantes des cyclines
MA28747B1 (fr) Dérivés de pyridine
MA31419B1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d&#39;une croissance cellulaire anormale
MA30344B1 (fr) Pyrazoles actifs sur la 11-beta-hsd-1
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
MA31754B1 (fr) Cis-imidazolines chirales
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA39043A1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
MA57000B1 (fr) Dérivés d&#39;alpha-d-galactopyranoside
MA31894B1 (fr) Composes organiques
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation